Stellenangebot: Postdoctoral Researcher – CAR T-Cell Development and Tumor Immunology (m/w/d) bei Klinikum der Universität München
Das Wichtigste im Überblick
Besondere Merkmale
Arbeitsort
MünchenAngebotsart
ArbeitAnstellungsart
VollzeitBerufsbezeichnung
- Biologielaborant/in
Stellenbeschreibung
Scope of duties
· Develop and optimize CAR constructs and support their transfer into a scalable retroviral vector system
· Generate and characterize CAR T cells and assess their functionality in vitro using AML cell lines and primary patient samples
· Investigate CAR T-cell cytotoxicity, activation, differentiation, and proliferation.
· Evaluate potential off-target effects and hematopoietic toxicity using humanized mouse models and healthy human tissue explant models
· Analyze experimental data, document results, and contribute to scientific publications and preclinical safety evaluation
· Collaborate with interdisciplinary research teams within the CARAMeL consortium
Our requirements
· PhD, MD, PharmD, DVM, or an equivalent doctoral degree in immunology, molecular or cell biology, biochemistry, biomedical sciences, or a related field
· Strong experimental research experience and a good publication record
· Solid knowledge of immunology and cell biology, with practical experience in cell culture and functional assays
· Experience in one or more of the following areas is highly desirable: CAR T-cell engineering, viral vector technology, flow cytometry, or preclinical in vivo models
· Strong analytical skills and an independent, structured approach to research
· High motivation, initiative, and the ability to work collaboratively in an international research environment
· Excellent written and spoken English
Our offer
· Contract duration: 2 years fixed-term
· The Institute of Clinical Pharmacology at LMU University Hospital Munich offers an interdisciplinary research environment at the interface of experimental immunology, innovative cell therapies, and translational medicine
· The research group of Prof. Dr. Sebastian Kobold focuses on developing novel cancer immunotherapies, particularly cellular therapies and antibody-based approaches
· This position is part of the CARAMeL consortium, funded by the German Cancer Consortium (DKTK). The project aims to advance an innovative CAR T-cell therapy for patients with relapsed or refractory acute myeloid leukemia (AML). A key objective is to improve therapeutic efficacy while minimizing damage to healthy hematopoietic stem and progenitor cells
· The successful candidate will contribute to translating the CAR technology into a scalable retroviral vector system and investigating the functionality and preclinical safety of the resulting CAR T cells. The work will be conducted in close collaboration with national and international research partners
Arbeitsorte
Unternehmensdarstellung: Klinikum der Universität München
In diesem Dokument befinden sich aus Sicherheitsgründen keine Kontaktdaten des Arbeitgebers. Wenn Sie diese sehen möchten, lösen Sie bitte die Sicherheitsfrage und laden Sie das PDF erneut.